Security
Inogen, Inc Common Stock · INGN
INGNNASDAQCommon stockCurrentCIK 1294133Updated Oct 6, 2026
INGN price & chart
Loading TradingView…
NASDAQ:INGN on TradingView ↗About the company
Inogen, Inc. (Nasdaq: INGN) is a medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other Events
Items 1.01, 7.01, 8.01, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 298,625,000Source | 296,185,000Source | 326,194,000Source | 405,041,000Source |
| Property, Plant and Equipment, NetUSD | 36,362,000Source | 44,400,000Source | 50,316,000Source | 43,269,000Source |
| GoodwillUSD | 10,698,000Source | 9,465,000Source | 10,057,000Source | 32,852,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,729,000Source | 113,795,000Source | 125,492,000Source | 187,014,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 38,863,000Source | 29,563,000Source | 42,241,000Source | 62,725,000Source |
| Inventory, NetUSD | 25,969,000Source | 24,812,000Source | 21,840,000Source | 34,093,000Source |
| Assets, CurrentUSD | 198,299,000Source | 185,451,000Source | 207,067,000Source | 304,645,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 12,601,000Source | 13,123,000Source | 13,846,000Source | 19,187,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,501,000Source | 18,295,000Source | 20,338,000Source | 21,653,000Source |
| Other Assets, NoncurrentUSD | 6,002,000Source | 8,081,000Source | 3,825,000Source | 2,445,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 106,394,000Source | 122,325,000Source | 121,382,000Source | 107,635,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 27,000Source | 24,000Source | 23,000Source | 23,000Source |
| Retained Earnings (Accumulated Deficit)USD | -175,584,000Source | -152,837,000Source | -116,949,000Source | -14,500,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,243,000Source | -1,501,000Source | 1,225,000Source | -243,000Source |
| Stockholders' Equity Attributable to ParentUSD | 192,231,000Source | 173,860,000Source | 204,812,000Source | 297,406,000Source |
| Additional Paid in Capital, Common StockUSD | 363,545,000Source | 328,174,000Source | 320,513,000Source | 312,126,000Source |
| Liabilities and EquityUSD | 298,625,000Source | 296,185,000Source | 326,194,000Source | 405,041,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 63,535,000Source | 76,686,000Source | 72,496,000Source | 65,349,000Source |
| Operating Lease, Liability, CurrentUSD | 3,163,000Source | 2,812,000Source | 3,653,000Source | 3,515,000Source |
| Accounts Payable, CurrentUSD | 20,264,000Source | 16,616,000Source | 13,454,000Source | 18,237,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,313,000Source | 16,594,000Source | 18,270,000Source | 19,764,000Source |
| Deferred Income Tax Liabilities, NetUSD | 6,749,000Source | 6,948,000Source | 8,539,000Source | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 6,749,000Source | 6,948,000Source | 8,539,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 20,659,000Source | 21,004,000Source | 18,152,000Source | 23,514,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,014,000Source | 7,397,000Source | 7,427,000Source | 12,283,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 14,624,000Source | 5,187,000Source | -10,141,000Source | 51,337,000Source |
| Increase (Decrease) in InventoriesUSD | 3,210,000Source | 3,538,000Source | -7,878,000Source | 5,601,000Source |
| Deferred Income Tax Expense (Benefit)USD | -1,100,000Source | -1,150,000Source | -251,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -11,216,000Source | 5,914,000Source | -3,234,000Source | -37,532,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 29,633,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -26,209,000Source | -13,975,000Source | -59,315,000Source | -10,877,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,523,000Source | 3,360,000Source | 5,218,000Source | 3,337,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 821,000Source | 546,000Source | 518,000Source | 1,355,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 24,182,000Source | 265,000Source | 960,000Source | 380,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -12,397,000Source | -8,077,000Source | -61,522,000Source | -48,510,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 105,018,000Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 320,000Source | 375,000Source | -703,000Source | 499,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,014,000Source | 7,397,000Source | 7,427,000Source | 12,283,000Source |
| Amortization of Intangible AssetsUSD | 4,920,000Source | 4,330,000Source | 1,202,000Source | 8,469,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | -52,161,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -57,000Source | 165,000Source | 84,000Source | 154,000Source |
| General and Administrative ExpenseUSD | 67,381,000Source | 72,578,000Source | 75,260,000Source | 43,905,000Source |
| GoodwillUSD | 10,698,000Source | 9,465,000Source | 10,057,000Source | 32,852,000Source |
| Goodwill, Impairment LossUSD | — | — | 32,894,000Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | -632,000Source | -588,000Source | 105,000Source | 504,000Source |
| Inventory Write-downUSD | 822,000Source | 233,000Source | 2,691,000Source | 2,423,000Source |
| Investment Income, InterestUSD | 4,385,000Source | 5,190,000Source | 6,574,000Source | 2,837,000Source |
| Net Income (Loss) Attributable to ParentUSD | -22,747,000Source | -35,888,000Source | -102,449,000Source | -83,772,000Source |
| Nonoperating Income (Expense)USD | 6,828,000Source | 6,040,000Source | 7,042,000Source | 1,975,000Source |
| Operating ExpensesUSD | 184,472,000Source | 197,257,000Source | 236,085,000Source | 238,776,000Source |
| Other Nonoperating Income (Expense)USD | 2,443,000Source | 850,000Source | 468,000Source | -862,000Source |
| Proceeds from Issuance of Common StockUSD | 27,210,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 384,000Source | 44,000Source |
| Restructuring CostsUSD | 0Source | 0Source | 3,426,000Source | — |
| Unrealized Gain (Loss) on DerivativesUSD | 0Source | 0Source | 0Source | -1,140,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 295,304,000Source | 278,756,000Source | 251,607,000Source | 320,549,000Source |
| Cost of RevenueUSD | 163,837,000Source | 148,655,000Source | 158,636,000Source | 197,805,000Source |
| Operating Income (Loss)USD | -30,207,000Source | -42,516,000Source | -109,386,000Source | -85,243,000Source |
| Other Nonoperating Income (Expense)USD | 2,443,000Source | 850,000Source | 468,000Source | -862,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -23,379,000Source | -36,476,000Source | -102,344,000Source | -83,268,000Source |
| Income Tax Expense (Benefit)USD | -632,000Source | -588,000Source | 105,000Source | 504,000Source |
| Net Income (Loss) Attributable to ParentUSD | -22,747,000Source | -35,888,000Source | -102,449,000Source | -83,772,000Source |
| Earnings Per Share, BasicUSD per share | -0.86Source | -1.52Source | -4.42Source | -3.67Source |
| Earnings Per Share, DilutedUSD per share | -0.86Source | -1.52Source | -4.42Source | -3.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 26,601,652Source | 23,654,395Source | 23,176,098Source | 22,852,571Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 26,601,652Source | 23,654,395Source | 23,176,098Source | 22,852,571Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 4,920,000Source | 4,330,000Source | 1,202,000Source | 8,469,000Source |
| Cost of Property Repairs and MaintenanceUSD | 7,071,000Source | 6,413,000Source | 5,143,000Source | 4,528,000Source |
| Current Income Tax Expense (Benefit)USD | 406,000Source | 422,000Source | 356,000Source | 504,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 15,739,000Source | 16,674,000Source | 16,950,000Source | 15,045,000Source |
| General and Administrative ExpenseUSD | 67,381,000Source | 72,578,000Source | 75,260,000Source | 43,905,000Source |
| Goodwill, Impairment LossUSD | — | — | 32,894,000Source | 0Source |
| Gross ProfitUSD | 154,265,000Source | 154,741,000Source | 126,699,000Source | 153,533,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -17,078,000Source | -29,143,000Source | -99,015,000Source | -84,422,000Source |
| Investment Income, InterestUSD | 4,385,000Source | 5,190,000Source | 6,574,000Source | 2,837,000Source |
| Nonoperating Income (Expense)USD | 6,828,000Source | 6,040,000Source | 7,042,000Source | 1,975,000Source |
| Operating ExpensesUSD | 184,472,000Source | 197,257,000Source | 236,085,000Source | 238,776,000Source |
| Research and Development ExpenseUSD | 19,399,000Source | 21,610,000Source | 20,840,000Source | 21,943,000Source |
| Restructuring CostsUSD | 0Source | 0Source | 3,426,000Source | — |
| Selling and Marketing ExpenseUSD | 97,692,000Source | 103,069,000Source | 107,091,000Source | 120,767,000Source |
Filing attachments
ingn-ex99_1.htm · 8-K · 2026-09-30
Exhibit 99.1 INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH Transaction advances Inogen’s strategic shift toward a more streamlined commercial model supporting higher revenue growth and adjusted operating income BEVERLY, Mass., September 30, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has signed a definitive agreement to divest its U.S. oxygen ren…
Read attachment ↗ingn-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 ingn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2026. “Our second qu…
Read attachment ↗ingn-ex99_1.htm · S-8 · 2026-07-24
Exhibit 99.1 INOGEN, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) The award (“Award”) provided pursuant to this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A. Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (th…
Read attachment ↗ingn-ex99_1.htm · 8-K · 2026-07-01
EX-99.1 3 ingn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Inogen Announces the Appointment of Andy Reding as Chief Operating Officer Newly created role strengthens leadership structure to support Inogen’s global commercial and operational execution BEVERLY, Mass., July 1, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief …
Read attachment ↗ingn-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 ingn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Inogen Announces First Quarter 2026 Financial Results Reported first quarter year-over-year revenue growth of 3.4% Company reiterates full-year 2026 guidance BEVERLY, Mass., May 7, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance. “Our…
Read attachment ↗ingn-ex99_1.htm · S-8 · 2026-05-04
Exhibit 99.1 INOGEN, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT (TIME-BASED) The award (“Award”) provided pursuant to this Restricted Stock Unit Agreement (Time-Based) (this “Award Agreement”), which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A. Unless otherwise defined herein, the terms defined in the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan (th…
Read attachment ↗